다우존스 지수

같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

등록

홈
인베스팅
주식
미국
NYSE
Johnson and Johnson (JNJ)
Johnson and Johnson (JNJ) 뉴스

JNJ

Johnson and Johnson (JNJ)

Johnson and Johnson

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NYSE:JNJ

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/07/31	10:06	Edgar (US Regulatory)	Form SC 13G - Statement of Beneficial Ownership by Certain Investors	NYSE:JNJ	Johnson and Johnson
2024/07/31	07:42	PR Newswire (US)	DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligible	NYSE:JNJ	Johnson and Johnson
2024/07/30	19:00	IH Market News	Toyota Reports Another Global Production Decline, Delta Sues CrowdStrike, Meta Launches AI Studio for Custom Chatbots	NYSE:JNJ	Johnson and Johnson
2024/07/30	05:00	Business Wire	Johnson & Johnson to Participate in the 2024 Wells Fargo Healthcare Conference	NYSE:JNJ	Johnson and Johnson
2024/07/26	22:38	Business Wire	Courts, Congress Likely to Stand in Way of J&J’s Third Texas Two-Step Plan	NYSE:JNJ	Johnson and Johnson
2024/07/26	22:05	Business Wire	FINAL DEADLINE: Ovarian Cancer Victims Have Until 5pm ET Today to Vote on Approximately $8 Billion J&J Talc Compensation Plan	NYSE:JNJ	Johnson and Johnson
2024/07/26	19:07	IH Market News	Alphabet Unveils AlphaProof and AlphaGeometry 2; OpenAI Tests SearchGPT; Apple Loses Market Share in China	NYSE:JNJ	Johnson and Johnson
2024/07/26	05:02	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NYSE:JNJ	Johnson and Johnson
2024/07/24	05:00	Business Wire	Johnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference	NYSE:JNJ	Johnson and Johnson
2024/07/23	00:59	Business Wire	Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J’s Latest Bankruptcy Plan	NYSE:JNJ	Johnson and Johnson
2024/07/22	21:00	PR Newswire (US)	Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression	NYSE:JNJ	Johnson and Johnson
2024/07/17	21:14	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:JNJ	Johnson and Johnson
2024/07/17	19:30	IH Market News	Tech-Led Decline in U.S. Index Futures Pre-Market, Oil Prices Steady After U.S. Inventory Drop	NYSE:JNJ	Johnson and Johnson
2024/07/17	19:28	IH Market News	Spirit Airlines Cuts Revenue Forecast, J.B. Hunt Disappoints Analysts’ Estimates, and More Earnings Updates	NYSE:JNJ	Johnson and Johnson
2024/07/17	19:25	Business Wire	Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2024	NYSE:JNJ	Johnson and Johnson
2024/07/17	19:20	Business Wire	Johnson & Johnson reports Q2 2024 results	NYSE:JNJ	Johnson and Johnson
2024/07/11	20:30	Business Wire	Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26	NYSE:JNJ	Johnson and Johnson
2024/07/10	06:48	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:JNJ	Johnson and Johnson
2024/07/03	21:00	PR Newswire (Canada)	Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations	NYSE:JNJ	Johnson and Johnson
2024/07/03	21:00	PR Newswire (Canada)	Santé Canada autorise le traitement par RYBREVANT® (amivantamab) en association avec le carboplatine et le pemetrexed comme seul traitement de première intention ciblé approuvé pour les patients atteints d'un cancer du poumon non à petites cellules p	NYSE:JNJ	Johnson and Johnson
2024/07/02	20:30	PR Newswire (US)	CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study	NYSE:JNJ	Johnson and Johnson
2024/06/29	00:30	PR Newswire (US)	Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients	NYSE:JNJ	Johnson and Johnson
2024/06/28	07:46	Business Wire	Lawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in Purdue	NYSE:JNJ	Johnson and Johnson
2024/06/21	20:30	Business Wire	Johnson & Johnson Completes Acquisition of Proteologix, Inc.	NYSE:JNJ	Johnson and Johnson
2024/06/21	05:30	PR Newswire (US)	Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease	NYSE:JNJ	Johnson and Johnson
2024/06/21	02:07	Business Wire	More than 60 Law Firms Oppose J&J Prepack Bankruptcy Scheme	NYSE:JNJ	Johnson and Johnson
2024/06/20	21:00	PR Newswire (US)	TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction	NYSE:JNJ	Johnson and Johnson
2024/06/20	19:55	IH Market News	Trump Media Resells Stocks and Warrants; KB Home Exceeds Q2 Expectations, and More News	NYSE:JNJ	Johnson and Johnson
2024/06/18	06:55	Business Wire	Beasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc Products	NYSE:JNJ	Johnson and Johnson
2024/06/17	21:00	PR Newswire (US)	Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer	NYSE:JNJ	Johnson and Johnson

검색 관련기사 보기:NYSE:JNJ

1 2 3 4 5 6 7 8 9 10 다음 >>

Health Care Select Sector

Verizon Communications

US Dollar vs Yen

Energy Select Sector SPDR

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관